191671-18-8

Upstream product

• 4521-61-3 3,4,5-Trimethoxybenzoyl chloride 
• 54767-81-6 5-(epoxyethyl)-1,2,3-tris(methoxy)benzene 
• 67-63-0 isopropyl alcohol 
• 1136-86-3 methyl (3,4,5-trimethoxyphenyl) ketone 

Downstream Products

• 191670-79-8 (Z)-3-(Indol-3-yl)-2-methoxy-1-(3,4,5-trimethoxyphenyl)-2-propen-1-one 
• 527750-23-8 (Z)-3-(3-hydroxy-4-methoxyphenyl)-2-methoxy-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 
• 527750-36-3 (Z)-3-(3-fluoro-4-methoxyphenyl)-2-methoxy-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 
• 524945-14-0 (Z)-3-(3,5-difluoro-4-methoxyphenyl)-2-methoxy-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 
• 1416991-13-3 (Z)-1-(2-methoxy-1-(3,4,5-trimethoxyphenyl)-ethylidene)-2-tosylhydrazine 
• 1416991-16-6 (E)-1-(2-methoxy-1-(3,4,5-trimethoxyphenyl)-ethylidene)-2-tosylhydrazine 

Relevant academic research and scientific papers

Synthesis, biological evaluation, and structure-activity relationships of tri- and tetrasubstituted olefins related to isocombretastatin A-4 as new tubulin inhibitors

The synthesis and structure-activity relationships associated with a series of 1,1-diarylethylene tubulin polymerization inhibitors 3 and 4 are described. The key step for their preparation involves a palladium-catalyzed coupling of N-arylsulfonylhydrazon

Propenone derivatives

The present invention relates to propenone derivatives represented by the following formula (I): STR1 wherein R1 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, or YR5 (wherein Y represents S or O; and R5 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a substituted or unsubstituted cyclic ether residue); R2 and R3 independently represent hydrogen, lower alkyl, or substituted or unsubstituted aralkyl, or alternatively R2 and R3 are combined to form substituted or unsubstituted methylene or ethylene; R4 represents hydrogen, hydroxy, lower alkyl, substituted or unsubstituted aralkyl, lower alkoxy, substituted or unsubstituted aralkyloxy, or halogen; and X represents substituted or unsubstituted indolyl; or pharmaceutically acceptable salts thereof.

PROPENONE DERIVATIVES

The present invention relates to propenone derivatives represented by the following formula (I): wherein R1represents substituted lower alkyl or YR5(wherein Y represents S or O, and R5represents substituted or unsubstitute